Although the Donnelly et al. study analyzed data from melanoma patients, their results clearly illustrated that monotherapy ICI (ex: anti-PD-1) can lead to very different outcomes versus combination ICIs (anti-PD-1 + anti-CTLA-4) (37). This evidence concerns the gene PDCD1 and melanoma.